| Autor: |
Pinto, Carmine, Normanno, Nicola, Orlandi, Armando, Fenizia, Francesca, Damato, Angela, Maiello, Evaristo, Tamburini, Emiliano, Di Costanzo, Francesco, Tonini, Giuseppe, Bilancia, Domenico, Corsi, Domenico, Pisconti, Salvatore, Ferrau, Francesco, Gori, Stefania, Daniele, Bruno, Zaniboni, Alberto, Soto Parra, Héctor, Frassinetti, Giovanni Luca, Iaffaioli, Rosario Vincenzo, Cassata, Antonio |
| Zdroj: |
Future Oncology; Jun2018, Vol. 14 Issue 14, p1339-1346, 8p |
| Abstrakt: |
The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy might result only in increased toxicity. In unresectable metastatic RAS and BRAF wt colorectal cancer patients, a deintensified therapy could represent a valuable option that might preserve quality of life. We designed a study to compare FOLFIRI/cetuximab to FOLFIRI/cetuximab for eight cycles followed by cetuximab alone in first-line treatment of RAS and BRAF (wt) metastatic colorectal cancer patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
